证券研究报告 | 年报点评报告 gszqdatemark 2025 05 01 年 月 日 粤电力 A（000539.SZ） 电价下滑拖累业绩，成本下行静待盈利修复 公司发布 2024 年年报及 2025 年一季报。2024 年公司实现营业收入 571.59 亿元，同比-4.27%；实现归母净利润 9.64 亿元，同比减少 1.07%； 实现归母扣非净利润 9.31 亿元，同比减少 14.86%。2025 年一季度，公 司实现营业收入 105.73 亿元，同比减少 17.33%；归母净利润亏损 3.83 亿元，同比减少 403%；归母扣非净利润亏损 4.17 亿元，同比减少 537%。 -30% -20% -10% 0% 10% 20% 2024-04 2024-08 2024-12 2025-04 粤电力A 沪深300 气电&新能源新增投产带动量增，成本回落对冲电价下滑承压。电量方面， 2024 年公司发电量 1258 亿千瓦时，同比+4.38%；其中煤电/气电/风电/ 光伏/水电/生物质分别发电量 913/257/52/25/4/7 亿千瓦时，分别- 4.51%/+38.77%/+5.5%/551.69% ...

Investment Rating - The investment rating for Chengdu Bank is "Accumulate" with a 6-month outlook [7] Core Views - Chengdu Bank reported a revenue of approximately 5.8 billion yuan for Q1 2025, representing a year-on-year increase of 3.17%. The net profit attributable to shareholders was 3 billion yuan, up 5.64% year-on-year. The non-performing loan ratio stood at 0.66%, with a provision coverage ratio of 456% [1][2][4] Financial Performance Summary - In Q1 2025, Chengdu Bank's net interest income was 4.8 billion yuan, accounting for 82.6% of total revenue, with a year-on-year growth of 3.75%. Non-interest income reached 1 billion yuan, showing a significant increase of 17.43% [2] - The bank's net interest margin recorded at 1.62%, down 4 basis points quarter-on-quarter, primarily due to adjustments in the Loan Prime Rate (LPR) affecting the re-pricing of existing loans [3] - Total interest-earning assets amounted to 1.32 trillion yuan, reflecting a year-on-year growth of 13.3%, with loans and financial investments being the main growth drivers [3][4] Asset Quality and Capital Adequacy - Chengdu Bank's non-performing loan balance was 530 million yuan, maintaining a non-performing loan ratio of 0.66% compared to 2024. The provision coverage ratio decreased by 23.3 percentage points from the end of 2024 [4] - The core Tier 1 capital adequacy ratio was recorded at 8.84%, down 22 basis points, attributed to the expansion of risk-weighted assets due to sustained credit growth [4] Profit Forecast and Valuation - The forecasted growth rates for net profit attributable to shareholders from 2025 to 2027 are 9.18%, 8.84%, and 6.48%, respectively, with corresponding book values per share (BPS) of 23.20, 27.66, and 32.29 yuan [5] - Financial projections indicate a steady increase in operating revenue, with expected figures of 243 billion yuan in 2025, 261 billion yuan in 2026, and 275 billion yuan in 2027 [6][12]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [6]. Core Views - The company reported a revenue of 3.07 billion yuan for 2024, a year-on-year increase of 36.5%, while the net profit attributable to shareholders decreased by 33.6% to 300 million yuan [1]. - In Q1 2025, the company achieved a revenue of 820 million yuan, reflecting a year-on-year growth of 54.1%, although it showed a quarter-on-quarter decline of 37.9% [1]. - The veterinary biological products segment saw significant growth, with revenues from veterinary biological products increasing by 23.4% to 1.32 billion yuan, while the pet supply chain grew by 37.7% to 630 million yuan [2]. - The company is focusing on enhancing its research and development efforts, with R&D expenditure as a percentage of revenue rising from 5.9% in 2021 to 6.4% in 2024 [3]. - The strategic acquisition of a 56.3% stake in Zhongrui Supply Chain is aimed at strengthening the company's position in the pet health market and enhancing distribution channels [4]. Summary by Sections Financial Performance - For 2024, the company expects total revenue to reach 3.07 billion yuan, with a growth rate of 13.3% [5]. - The projected net profit for 2025 is 493 million yuan, representing a significant recovery with a growth rate of 63.9% [5]. - Earnings per share (EPS) are forecasted to be 1.06 yuan in 2025, with a price-to-earnings (PE) ratio of 19 [5]. Business Segments - The veterinary formulation and raw materials segment experienced a revenue decline of 6.4%, totaling 1.04 billion yuan [2]. - The company is actively launching new products, including a combination vaccine for cats and various core products for pets, to enhance market competitiveness [3]. Strategic Initiatives - The company is committed to increasing its R&D investments and has successfully launched domestically developed vaccines, breaking foreign monopolies [3]. - The share buyback program, which has repurchased 6.4 million shares (1.4% of total shares) for 120 million yuan, aims to boost investor confidence [4].

行业触及底部，有望迎来复苏 核心观点 盈利预测与投资建议 ⚫ 结合 2024 年原油与产品价格情况，以及公司已披露的生产经营与各项费率情况，我 们调整公司 2025 年每股收益 EPS 预测分别为 0.31 元（原预测 1.02 元），并添加 2026-2027 年预测为 0.39 和 0.49 元。我们采取历史估值法，参考公司过去 5 年 PB （TTM）均值 3.28，考虑到行业景气度底部以及预期 ROE 水平低于历史水平给予 20%折价，按 25 年每股净资产预测值 4.82 元对应目标价为 12.64 元，维持买入评 级。 风险提示 ⚫ 油价大幅波动；行业景气度下行；新材料项目发展不及预期。 公司主要财务信息 | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | 1.61 | -6.51 | -7.25 | -28.76 | | 相对表现% | 1.84 | -2.93 | -6.15 | -32.93 | | 沪深 300% | -0.23 | -3.58 | -1.1 | 4.17 | 倪吉 021-63325 ...

2025 年 04 月 29 日 公司点评 买入/维持 海泰新光(688677) 昨收盘:34.70 海泰新光点评报告：海外布局稳步推进，客户订单有望恢复 ◼ 走势比较 (50%) (36%) (22%) (8%) 6% 20% 24/4/29 24/7/11 24/9/22 24/12/4 25/2/15 25/4/29 ◼ 股票数据 | 总股本/流通(亿股) | 1.21/1.21 | | --- | --- | | 总市值/流通(亿元) | 41.85/41.85 | | 12 个月内最高/最低价 | 49.3/25.48 | | (元) | | 相关研究报告 <<海泰新光点评报告：短期受客户订 单周期影响，业绩恢复可期>>-- 2024-10-31 <<海泰新光点评报告：史赛克产品迭 代影响公司 23 年收入，24 年有望迎 来反转>>--2023-10-29 <<海泰新光点评报告：第二季度订单 波动，未来增长依然可期>>--2023- 09-03 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 研究助理 ...

2025 年 04 月 29 日 公司点评 买入/维持 惠泰医疗(688617) 昨收盘:427.10 惠泰医疗点评报告：业绩持续高增长，PFA 有望贡献新增量 ◼ 走势比较 (20%) (8%) 4% 16% 28% 40% 24/4/29 24/7/10 24/9/20 24/12/1 25/2/11 25/4/24 ◼ 股票数据 总股本/流通(亿股) 0.97/0.97 总市值/流通(亿元) 414.64/414.64 12 个月内最高/最低价 (元) 569/303.52 相关研究报告 <<惠泰医疗点评报告：业绩基本符合 预期，看好集采下产品放量>>-- 2024-11-01 <<惠泰医疗点评报告：电生理手术量 保持强劲增长，业绩持续向好>>-- 2024-08-27 <<惠泰医疗点评报告：电生理手术量 增速强劲，血管介入新品迭出>>-- 2024-04-26 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 研究助理：李啸岩 电话：0755-83683312 E-MAIL：lixiaoyan@tpyzq. ...

Investment Rating - The report maintains an "Outperform the Market" rating for the company [6][4]. Core Insights - The company reported a Q1 2025 revenue of 3.486 billion yuan, a year-on-year increase of 41.9%, but a quarter-on-quarter decrease of 19.0. The net profit attributable to shareholders was 2.715 billion yuan, up 39.0% year-on-year and down 23.9% quarter-on-quarter [1][4]. - The capital market's trading activity has significantly increased since Q4 2024, driving substantial growth in the company's securities business, particularly in brokerage and margin financing [1][2]. - The company has increased its bond investments in recent years, which has contributed positively to its revenue [1]. - The company holds a leading position in fund distribution, with a total equity fund holding of 349.3 billion yuan, accounting for 60.7% of non-monetary funds [3]. - The company has a strong online presence with its platforms, which enhances user engagement and retention, and it possesses a comprehensive range of financial licenses [3]. Financial Performance and Forecast - The company’s projected revenues for 2025-2027 are 13.265 billion yuan, 14.729 billion yuan, and 16.359 billion yuan, respectively, reflecting growth rates of 14.3%, 11.0%, and 11.1% [5][29]. - The net profit attributable to shareholders is expected to reach 11.010 billion yuan in 2025, with a growth rate of 14.6% [5][29]. - The company’s current price-to-earnings (P/E) ratio is 34.00x, which is at the 48.43% percentile over the past five years [4][26].

2025 年 04 月 29 日 公司点评 买入/首次 ◼ 股票数据 总股本/流通(亿股) 48.47/48.47 总市值/流通(亿元) 677.17/677.17 12 个月内最高/最低价 (元) 18.65/11.86 相关研究报告 中金黄金(600489) 证券分析师：刘强 电话： E-MAIL：liuqiang@tpyzq.com 分析师登记编号：S1190522080001 证券分析师：梁必果 电话： E-MAIL：liangbg@tpyzq.com 昨收盘:13.97 事件：2025 年 4 月 30 日，公司发布 2024 年年报及 2025 年一季报。 2024 年公司实现收入 655.56 亿元，同比+7.01%；归母净利润 33.86 亿 元，同比+13.71%；扣非净利润 35.32 亿元，同比+18.25%。2025 年一季 度，公司实现收入 148.59 亿元，同比+12.88%，环比-23.84%；归母净利 润 10.38 亿元，同比+32.65%，环比+39.79%；扣非净利润 12.68 亿元，同 比+71.13%，环比+38.76%。 业绩显著增长，盈利能力持续提升 ◼ 走势 ...

公司报告 | 季报点评 华利集团（300979） 证券研究报告 新厂爬坡短暂拖累盈利，新客户订单显著增长 公司发布一季报 25Q1 营收 54 亿，同增 12%，归母 7.6 亿，同减 3%，扣非后归母 7.5 亿， 同减 3%。 公司通过战略性拓展新客户及深化新兴运动品牌客户合作，2025Q1 新客户 订单量同比显著增长。为匹配快速增长产能需求，公司加速了新工厂的建 设和投产节奏（继 2024 年上半年和下半年各投产 2 家成品鞋工厂之后， 2025 年第一季度 2 家成品鞋工厂已经投产）。 鉴于新工厂投产初期存在新员工技能培训周期（2025 年 3 月末员工人数约 18.4 万人，较 2024 年 3 月末增加约 17%，其中最近半年集团员工人数增 加约 1.4 万人），新工厂仍处于效率爬坡阶段，对公司整体毛利率造成一定 影响。公司将通过优化培训机制、加快推进智能化生产设备和生产管理系 统部署等措施助力新工厂的运营效率提升。 新增客户以及新客户合作深入，是业绩稳健成长重要保障 公司客户相对多元，大多数客户都是上市公司。从各客户披露的业绩指引 来看，多数客户业绩保持成长。对于营收增速较高的客户，公司来自该客 ...

基地市场保持稳健增长，24 年控费成效凸 显 核心观点 25.9/8.58/5.50/2.30/10.99 亿元，同比+9.96%/-10.33%/+0.53%/+28.12%/+12.3%。 按地区划分，24 年全年河北/山东/安徽/湖南/其他省份分别实现收入 31.2/2.1/5.5/11.0/3.3 亿元，分别同比+2.6%/+31.4%/+0.5%/+12.3%/+20.7%。 25Q1 河北/山东/安徽/湖南/其他省份分别实现收入 7.2/0.4/1.3/2.1/0.6 亿元，分别同 比+8.0%/+7.9%/+2.5%/+9.7%/-36.6%。24 年年末，公司在河北/山东/安徽/湖南/其 他省份经销商数量分别环比 24Q3 末+16/+17/+13/-66/+13 家。25Q1 末，公司在河 北/山东/安徽/湖南/其他省份经销商数量分别环比 24 年年末+13/-22/+7/+73/+12 家。 ⚫ 24 年控费成果显现费用率降低，25 年营业利润目标增速为 12%。24 全年归母净利 率为 14.69%，同比增加 2.02pct；全年累计销售/管理/财务/研发费用率分别为 23.69%/7. ...